All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Latest news on high-risk NDMM
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Taiga Nishihori, Moffitt Cancer Center, Tampa, US. We asked, Does allogeneic hematopoietic stem cell transplantation (allo-HSCT) still have a role in high-risk MM?
Nishihori discusses results from the BMT CTN 1302 trial, a multicenter phase II study investigating ixazomib maintenance after allo-HSCT in patients with high-risk MM (NCT02440464).
Latest news on high-risk NDMM
Subscribe to get the best content related to multiple myeloma delivered to your inbox